niacin and dinoprost
niacin has been researched along with dinoprost in 8 studies
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Awad, JA; Morrow, JD; Oates, JA; Roberts, LJ | 1 |
| Freeman, DJ; Parbtani, A; Spence, JD; Stern, RH | 1 |
| Morrow, JD; Parsons, WG; Roberts, LJ | 1 |
| Awad, JA; Morrow, JD; Roberts, LJ | 1 |
| Amano, F; Fujimori, K | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
Trials
1 trial(s) available for niacin and dinoprost
| Article | Year |
|---|---|
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Other Studies
7 other study(ies) available for niacin and dinoprost
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.
Topics: Administration, Oral; Administration, Topical; Adult; Dinoprost; Erythema; Histamine Release; Humans; Mast Cells; Middle Aged; Niacin; Nicotinic Acids; Prostaglandin D2; Skin; Vasodilation | 1992 |
Tolerance to nicotinic acid flushing.
Topics: Administration, Oral; Dinoprost; Drug Tolerance; Humans; Niacin; Nicotinic Acids; Radioimmunoassay; Skin | 1991 |
Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid.
Topics: Adult; Chromatography, Ion Exchange; Dinoprost; Dinoprostone; Epoprostenol; Flushing; Histamine; Histamine Release; Humans; Niacin; Prostaglandin D2; Time Factors | 1989 |
Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation.
Topics: Anaphylaxis; Dinoprost; Drug Stability; Drug Storage; Female; Humans; Kinetics; Male; Mastocytosis; Niacin; Prostaglandin D2; Prostaglandins D; Time Factors; Urticaria Pigmentosa | 1994 |
Niacin promotes adipogenesis by reducing production of anti-adipogenic PGF2α through suppression of C/EBPβ-activated COX-2 expression.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; CCAAT-Enhancer-Binding Protein-beta; CCAAT-Enhancer-Binding Proteins; Cyclooxygenase 2; Dinoprost; Gene Expression Regulation; Mice; Niacin; Triglycerides | 2011 |